Is the use of lenalidome better than

This is a clinical trial in 278 locations to determine whether treating high-risk smoldering myeloma patients with lenalidomide is better than the "watch and wait" approach using no treatment. Results from a previous trial perfomed by a Spanish group (Dr. Mateos) showed considerable benefit in a similar study, so the study is being run in the U.S. on a large scale to accumulate more data. The study's Principal Investigator is Dr. Sagar Lonial, MD from Dana Farber and the target number of patients to join across the country is 370. More information on this trial, including study locations can be found here.
This is a clinical trial in 278 locations to determine whether treating high-risk smoldering myeloma patients with lenalidomide is better than the "watch and wait" approach using no treatment. Results from a previous trial perfomed by a Spanish group (Dr. Mateos) showed considerable benefit in a similar study, so the study is being run in the U.S. on a large scale to accumulate more data. The study's Principal Investigator is Dr. Sagar Lonial, MD from Dana Farber and the target number of patients to join across the country is 370. More information on this trial, including study locations can be found here.

about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation.
More on Navigating Your Health
Trending Articles





Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.